Effectiveness of practices to increase timeliness of providing targeted therapy for inpatients with bloodstream infections: A laboratory medicine best practices systematic review and meta-analysis

Clinical Microbiology Reviews

Volumn 29, Issue 1, 2015, Pages 59-103

  Buehler, Stephanie S ^a   Madison, Bereneice ^a   Snyder, Susan R ^a   Derzon, James H ^a   Cornish, Nancy E ^b   Saubolle, Michael A ^c,d   Weissfeld, Alice S ^e   Weinstein, Melvin P ^f   Liebow, Edward B ^a   Wolk, Donna M ^g  

^a BATTELLE MEMORIAL INSTITUTE   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^e Microbiology Specialists Incorporated   (United States)

^f ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^g GEISINGER HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC SENSITIVITY; ARTICLE; BLOODSTREAM INFECTION; DISEASE SURVEILLANCE; HUMAN; INCIDENCE; META ANALYSIS; MORBIDITY; MORTALITY; PATIENT SAFETY; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; QUALITY OF LIFE; REAL TIME POLYMERASE CHAIN REACTION; SYSTEMATIC REVIEW; CATHETER-RELATED INFECTIONS; DIAGNOSTIC TEST; HOSPITAL PATIENT; PERSONALIZED MEDICINE; PROCEDURES; SEPSIS; TIME FACTOR;

CATHETER-RELATED INFECTIONS; DIAGNOSTIC TESTS, ROUTINE; HUMANS; INPATIENTS; PRACTICE GUIDELINES AS TOPIC; PRECISION MEDICINE; SEPSIS; TIME FACTORS;

EID: 84948186061     PISSN: 08938512     EISSN: 10986618     Source Type: Journal    
DOI: 10.1128/CMR.00053-14     Document Type: Article

References (81)

1. Christenson RH, Snyder SR, Shaw CS, Derzon JH, Black RS, Mass D, Epner P, Favoretto AM, Liebow EB. 2011. Laboratory medicine best practices: systematic evidence reviewandevaluation methods for quality improvement. Clin Chem 57: 816-825. http://dx.doi.org/10.1373/clinchem.2010.157131.
2. Bearman GM, Wenzel RP. 2005. Bacteremias: a leading cause of death. Arch Med Res 36: 646-659. http://dx.doi.org/10.1016/j.arcmed.2005.02.005.
3. Beekmann SE, Diekema DJ, Chapin KC, Doern GV. 2003. Effects of rapid detection of bloodstream infections on length of hospitalization and hospital charges. J Clin Microbiol 41: 3119-3125. http://dx.doi.org/10.1128/JCM.41.7.3119-3125.2003.
4. Marchetti O, Calandra T. 2002. Infections in neutropenic cancer patients. Lancet 359: 723-725. http://dx.doi.org/10.1016/S0140-6736(02)07900-X.
5. Pittet D, Tarara D, Wenzel RP. 1994. Nosocomial bloodstream infection in critically ill patients. Excess length of stay, extra costs, and attributable mortality. JAMA 271: 1598-1601.
6. Klevens RM, Edwards JR, Gaynes RP. 2008. The impact of antimicrobial-resistant, health care-associated infections on mortality in the United States. Clin Infect Dis 47: 927-930. http://dx.doi.org/10.1086/591698.
7. Hall M, Levant S, DeFrances C. 2013. Trends in inpatient hospital deaths: National Hospital Discharge Survey, 2000-2010. NCHS Data Brief 118. National Center for Health Statistics, Centers for Disease Control and Prevention, Atlanta, GA.
8. Liu V, Escobar GJ, Greene JD, Soule J, Whippy A, Angus DC, Iwashyna TJ. 2014. Hospital deaths in patients with sepsis from 2 independent cohorts. JAMA 312: 90-92. http://dx.doi.org/10.1001/jama.2014.5804.
9. Elixhauser A, Friedman B, Stranges E. 2006. Septicemia in U.S. hospitals, 2009: HCUP Statistical Brief 122. Agency for Healthcare Research and Quality, Rockville, MD.
10. Beekmann SE, Diekema DJ, Doern GV. 2005. Determining the clinical significance of coagulase-negative staphylococci isolated from blood cultures. Infect Control Hosp Epidemiol 26: 559-566. http://dx.doi.org/10.1086/502584.
11. Kaye KS, Marchaim D, Chen TY, Baures T, Anderson DJ, Choi Y, Sloane R, Schmader KE. 2014. Effect of nosocomial bloodstream infections on mortality, length of stay, and hospital costs in older adults. J Am Geriatr Soc 62: 306-311. http://dx.doi.org/10.1111/jgs.12634.
12. Gaieski DF, Mikkelsen ME, Band RA, Pines JM, Massone R, Furia FF, Shofer FS, Goyal M. 2010. Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department. Crit Care Med 38: 1045-1053. http://dx.doi.org/10.1097/CCM.0b013e3181cc4824.
13. Kumar A. 2014. Antimicrobial delay and outcome in severe sepsis. Crit Care Med 42: e802. http://dx.doi.org/10.1097/CCM.0000000000000620.
14. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, Gurka D, Kumar A, Cheang M. 2006. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 34: 1589-1596. http://dx.doi.org/10.1097/01.CCM.0000217961.75225.E9.
15. Brown J, Paladino JA. 2010. Impact of rapid methicillin-resistant Staphylococcus aureus polymerase chain reaction testing on mortality and cost effectiveness in hospitalized patients with bacteraemia: a decision model. Pharmacoeconomics 28: 567-575. http://dx.doi.org/10.2165/11533020-000000000-00000.
16. Brozanski BS, Jones JG, Krohn MJ, Jordan JA. 2006. Use of polymerase chain reaction as a diagnostic tool for neonatal sepsis can result in a decrease in use of antibiotics and total neonatal intensive care unit length of stay. J Perinatol 26: 688-692. http://dx.doi.org/10.1038/sj.jp.7211597.
17. Diab M, El-Damarawy M, Shemis M. 2008. Rapid identification of methicillin-resistant staphylococci bacteremia among intensive care unit patients. Medscape J Med 10: 126.
18. Savinelli T, Parenteau S, Mermel LA. 2004. What happens when automated blood culture instrument detect growth but there are no technologists in the microbiology laboratory? Diagn Microbiol Infect Dis 48: 173-174. http://dx.doi.org/10.1016/j.diagmicrobio.2003.10.001.
19. Baron EJ, Weinstein MP, Dunne WM, Jr, Yagupsky P, Welch DF, Wilson DM. 2005. Cumitech 1C, Blood cultures IV. Coordinating ed, Baron EJ. ASM Press, Washington, DC.
20. Peters RP, van Agtmael MA, Simoons-Smit AM, Danner SA, Vandenbroucke-Grauls CM, Savelkoul PH. 2006. Rapid identification of pathogens in blood cultures with a modified fluorescence in situ hybridization assay. J Clin Microbiol 44: 4186-4188. http://dx.doi.org/10.1128/JCM.01085-06.
21. Arbo MD, Snydman DR. 1994. Influence of blood culture results on antibiotic choice in the treatment of bacteremia. Arch Intern Med 154: 2641-2645. http://dx.doi.org/10.1001/archinte.1994.00420230024004.
22. Bouza E, Sousa D, Munoz P, Rodriguez-Creixems M, Fron C, Lechuz JG. 2004. Bloodstream infections: a trial of the impact of different methods of reporting positive blood culture results. Clin Infect Dis 39: 1161-1169. http://dx.doi.org/10.1086/424520.
23. Schonheyder HC, Hojbjerg T. 1995. The impact of the first notification of positive blood cultures on antibiotic therapy. A one-year survey. APMIS 103: 37-44.
24. Weinstein MP, Murphy JR, Reller LB, Lichtenstein KA. 1983. The clinical significance of positive blood cultures: a comprehensive analysis of 500 episodes of bacteremia and fungemia in adults. II. Clinical observations, with special reference to factors influencing prognosis. Rev Infect Dis 5: 54-70.
25. Wellinghausen N, Kochem AJ, Disque C, Muhl H, Gebert S, Winter J, Matten J, Sakka SG. 2009. Diagnosis of bacteremia in whole-blood samples by use of a commercial universal 16S rRNA gene-based PCR and sequence analysis. J Clin Microbiol 47: 2759-2765. http://dx.doi.org/10.1128/JCM.00567-09.
26. Cunney RJ, McNamara EB, Alansari N, Loo B, Smyth EG. 1997. The impact of blood culture reporting and clinical liaison on the empiric treatment of bacteraemia. J Clin Pathol 50: 1010-1012. http://dx.doi.org/10.1136/jcp.50.12.1010.
27. Dunagan WC, Woodward RS, Medoff G, Gray JL, III, Casabar E, Smith MD, Lawrenz CA, Spitznagel E. 1989. Antimicrobial misuse in patients with positive blood cultures. Am J Med 87: 253-259. http://dx.doi.org/10.1016/S0002-9343(89)80146-9.
28. Forrest GN, Mankes K, Jabra-Rizk MA, Weekes E, Johnson JK, Lincalis DP, Venezia RA. 2006. Peptide nucleic acid fluorescence in situ hybridization-based identification of Candida albicans and its impact on mortality and antifungal therapy costs. J Clin Microbiol 44: 3381-3383. http://dx.doi.org/10.1128/JCM.00751-06.
29. Fridkin SK, Edwards JR, Pichette SC, Pryor ER, McGowan JE, Jr, Tenover FC, Culver DH, Gaynes RP. 1999. Determinants of vancomycin use in adult intensive care units in 41 United States hospitals. Clin Infect Dis 28: 1119-1125. http://dx.doi.org/10.1086/514752.
30. Muto CA, Jernigan JA, Ostrowsky BE, Richet HM, Jarvis WR, Boyce JM, Farr BM. 2003. SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and enterococcus. Infect Control Hosp Epidemiol 24: 362-386. http://dx.doi.org/10.1086/502213.
31. Zhan C, Miller MR. 2003. Excess length of stay, charges, and mortality attributable to medical injuries during hospitalization. JAMA 290: 1868-1874. http://dx.doi.org/10.1001/jama.290.14.1868.
32. CLSI. 2007. Principles and procedures for blood cultures. Approved guidelines. CLSI, Wayne, PA.
33. Munson EL, Diekema DJ, Beekmann SE, Chapin KC, Doern GV. 2003. Detection and treatment of bloodstream infection: laboratory reporting and antimicrobial management. J Clin Microbiol 41: 495-497. http://dx.doi.org/10.1128/JCM.41.1.495-497.2003.
34. Centers for Disease Control and Prevention. 2014. Rapid diagnostic tests: how they work. Centers for Disease Control and Prevention, Atlanta, GA. http://www.cdc.gov/malaria/malaria_worldwide/reduction/dx_rdt.html.
35. World Health Organization. 2014. Simple/rapid tests. World Health Organization, Geneva, Switzerland. http://www.who.int/diagnostics_laboratory/faq/simple_rapid_tests/en/.
36. Garcia LS (ed). 2010. Clinical microbiology procedures handbook, 3rd ed. ASM Press, Washington, DC.
37. Versalovic J, Carroll KC, Funke G, Jorgensen JH, Landry ML, Warnock DW (ed). 2011. Manual of clinical microbiology, 10th ed. ASM Press, Washington, DC.
38. Chorny JA, Wilson ML. 1994. Rapid detection and identification of microorganisms from blood cultures. Clin Lab Med 14: 181-195.
39. Huttunen R, Syrjanen J, Vuento R, Aittoniemi J. 2013. Current concepts in the diagnosis of blood stream infections. Are novel molecular methods useful in clinical practice? Int J Infect Dis 17: e934-e938. http://dx.doi.org/10.1016/j.ijid.2013.04.018.
40. Marlowe EM, Wolk DM. 2006. Pathogen detection in the genomic era, p 505-525. In Tang Y (ed), Advanced techniques in diagnostic microbiology. Springer Verlag, New York, NY.
41. Pence MA, McElvania TE, Burnham CA. 2013. Diagnostic assays for identification of microorganisms and antimicrobial resistance determinants directly from positive blood culture broth. Clin Lab Med 33: 651-684. http://dx.doi.org/10.1016/j.cll.2013.03.010.
42. Riedel S, Carroll KC. 2013. Laboratory detection of sepsis: biomarkers and molecular approaches. Clin Lab Med 33: 413-437. http://dx.doi.org/10.1016/j.cll.2013.03.006.
43. Barenfanger J, Graham DR, Kolluri L, Sangwan G, Lawhorn J, Drake CA, Verhulst SJ, Peterson R, Moja LB, Ertmoed MM, Moja AB, Shevlin DW, Vautrain R, Callahan CD. 2008. Decreased mortality associated with prompt Gram staining of blood cultures. Am J Clin Pathol 130: 870-876. http://dx.doi.org/10.1309/AJCPVMDQU2ZJDPBL.
44. Institute of Medicine. 2011. Finding what works in healthcare: standards for systematic reviews. National Academies Press, Washington, DC.
45. Borenstein M. 2009. Effect sizes for continuous data, p 221-235. In Cooper H, Hedges L, Valentine J (ed), The handbook of research synthesis, 2nd ed. Russell Sage, New York, NY.
46. Borenstein M, Hedges L, Higgins J, Rothsteins H. 2009. Introduction to meta-analysis. Chichester, West Sussex, United Kingdom.
47. Fleiss J, Berlin J. 2009. Effect size for dichotomous data, p 237-256. In Cooper H, Hedges L, Valentine J (ed), The handbook of research synthesis, 2nd ed. Russell Sage, New York, NY.
48. Hallin M, Maes N, Byl B, Jacobs F, De Gheldre Y, Struelens MJ. 2003. Clinical impact of a PCR assay for identification of Staphylococcus aureus and determination of methicillin resistance directly from blood cultures. J Clin Microbiol 41: 3942-3944. http://dx.doi.org/10.1128/JCM.41.8.3942-3944.2003.
49. Nguyen DT, Yeh E, Perry S, Luo RF, Pinsky BA, Lee BP, Sisodiya D, Baron EJ, Banaei N. 2010. Real-time PCR testing for mecA reduces vancomycin usage and length of hospitalization for patients infected with methicillin-sensitive staphylococci. J Clin Microbiol 48: 785-790. http://dx.doi.org/10.1128/JCM.02150-09.
50. Parta M, Goebel M, Thomas J, Matloobi M, Stager C, Musher DM. 2010. Impact of an assay that enables rapid determination of Staphylococcus species and their drug susceptibility on the treatment of patients with positive blood culture results. Infect Control Hosp Epidemiol 31: 1043-1048. http://dx.doi.org/10.1086/656248.
51. Frye AM, Baker CA, Rustvold DL, Heath KA, Hunt J, Leggett JE, Oethinger M. 2012. Clinical impact of a real-time PCR assay for rapid identification of staphylococcal bacteremia. J Clin Microbiol 50: 127-133. http://dx.doi.org/10.1128/JCM.06169-11.
52. Allaouchiche B, Jaumain H, Zambardi G, Chassard D, Freney J. 1999. Clinical impact of rapid oxacillin susceptibility testing using a PCR assay in Staphylococcus aureus bactaeremia. J Infect 39: 198-204. http://dx.doi.org/10.1016/S0163-4453(99)90049-X.
53. Holtzman C, Whitney D, Barlam T, Miller NS. 2011. Assessment of impact of peptide nucleic acid fluorescence in situ hybridization for rapid identification of coagulase-negative staphylococci in the absence of antimicrobial stewardship intervention. J Clin Microbiol 49: 1581-1582. http://dx.doi.org/10.1128/JCM.02461-10.
54. Forrest GN. 2007. PNA FISH: present and future impact on patient management. Expert Rev Mol Diagn 7: 231-236. http://dx.doi.org/10.1586/14737159.7.3.231.
55. Bauer KA, West JE, Balada-Llasat JM, Pancholi P, Stevenson KB, Goff DA. 2010. An antimicrobial stewardship program's impact with rapid polymerase chain reaction methicillin-resistant Staphylococcus aureus/S. aureus blood culture test in patients with S. aureus bacteremia. Clin Infect Dis 51: 1074-1080. http://dx.doi.org/10.1086/656623.
56. Forrest GN, Roghmann MC, Toombs LS, Johnson JK, Weekes E, Lincalis DP, Venezia RA. 2008. Peptide nucleic acid fluorescent in situ hybridization for hospital-acquired enterococcal bacteremia: delivering earlier effective antimicrobial therapy. Antimicrob Agents Chemother 52: 3558-3563. http://dx.doi.org/10.1128/AAC.00283-08.
57. Ly T, Gulia J, Pyrgos V, Waga M, Shoham S. 2008. Impact upon clinical outcomes of translation ofPNAFISH-generated laboratory data from the clinical microbiology bench to bedside in real time. Ther Clin Risk Manag 4: 637-640.
58. Heil EL, Daniels LM, Long DM, Rodino KG, Weber DJ, Miller MB. 2012. Impact of a rapid peptide nucleic acid fluorescence in situ hybridization assay on treatment of Candida infections. Am J Health Syst Pharm 69: 1910-1914. http://dx.doi.org/10.2146/ajhp110604.
59. Forrest GN, Mehta S, Weekes E, Lincalis DP, Johnson JK, Venezia RA. 2006. Impact of rapid in situ hybridization testing on coagulase-negative staphylococci positive blood cultures. J. Antimicrob Chemother 58: 154-158. http://dx.doi.org/10.1093/jac/dkl146.
60. Trenholme GM, Kaplan RL, Karakusis PH, Stine T, Fuhrer J, Landau W, Levin S. 1989. Clinical impact of rapid identification and susceptibility testing of bacterial blood culture isolates. J Clin Microbiol 27: 1342-1345.
61. Kerremans JJ, Verboom P, Stijnen T, Hakkaart-van Roijen L, Goessens W, Verbrugh HA, Vos MC. 2008. Rapid identification and antimicrobial susceptibility testing reduce antibiotic use and accelerate pathogendirected antibiotic use. J Antimicrob Chemother 61: 428-435.
62. Bruins M, Oord H, Bloembergen P, Wolfhagen M, Casparie A, Degener J, Ruijs G. 2005. Lack of effect of shorter turnaround time of microbiological procedures on clinical outcomes: a randomised controlled trial among hospitalised patients in the Netherlands. Eur J Clin Microbiol Infect Dis 24: 305-313. http://dx.doi.org/10.1007/s10096-005-1309-7.
63. Doern GV, Vautour R, Gaudet M, Levy B. 1994. Clinical impact of rapid in vitro susceptibility testing and bacterial identification. J Clin Microbiol 32: 1757-1762.
64. Drummond MF, Jefferson TO, the BMJ Economic Evaluation Working Party. 1996. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 313: 275-283. http://dx.doi.org/10.1136/bmj.313.7052.275.
65. Drummond MF, O'Brien B, Stoddart G. 1997. Methods for the economic evaluation of health care programmes. Oxford Medical Publications, Oxford, United Kingdom.
66. Gabriel S, Drummond M, Maetzel A, Boers M, Coyle D, Welch V, Tugwell P. 2003. OMERACT 6 Economics Working Group report: a proposal for a reference case for economic evaluation in rheumatoid arthritis. J Rheumatol 30: 886-890.
67. World Health Organization. 2011. The burden of health care-associated infection worldwide. World Health Organization, Geneva, Switzerland.
68. O'Kane DJ, Ebert TA, Hallaway BJ, Roberts SG, Bhuiyan AK, Tenner KS. 1997. A laboratorian's perspective on evaluation and implementation of new laboratory tests. Clin Chem 43: 1771-1780.
69. Rigby S, Procop GW, Haase G, Wilson D, Hall G, Kurtzman C, Oliveira K, Von Oy S, Hyldig-Nielsen JJ, Coull J, Stender H. 2002. Fluorescence in situ hybridization with peptide nucleic acid probes for rapid identification of Candida albicans directly from blood culture bottles. J Clin Microbiol 40: 2182-2186. http://dx.doi.org/10.1128/JCM.40.6.2182-2186.2002.
70. Jordan JA, Durso MB. 2005. Real-time polymerase chain reaction for detecting bacterial DNA directly from blood of neonates being evaluated for sepsis. J Mol Diagn 7: 575-581. http://dx.doi.org/10.1016/S1525-1578 (10)60590-9.
71. Banada PP, Chakravorty S, Shah D, Burday M, Mazzella FM, Alland D. 2012. Highly sensitive detection of Staphylococcus aureus directly from patient blood. PLoS One 7: e31126. http://dx.doi.org/10.1371/journal.pone.0031126.
72. Maaroufi Y, Heymans C, De Bruyne JM, Duchateau V, Rodriguez-Villalobos H, Aoun M, Crokaert F. 2003. Rapid detection of Candida albicans in clinical blood samples by using a TaqMan-based PCR assay. J Clin Microbiol 41: 3293-3298. http://dx.doi.org/10.1128/JCM.41.7.3293-3298.2003.
73. Pereira TV, Horwitz RI, Ioannidis JP. 2012. Empirical evaluation of very large treatment effects of medical interventions. JAMA 308: 1676-1684. http://dx.doi.org/10.1001/jama.2012.13444.
74. Clerc O, Prod'hom G, Senn L, Jaton K, Zanetti G, Calandra T, Greub G. 2014. Matrix-assisted laser desorption ionization time-of-flight mass spectrometry and PCR-based rapid diagnosis of Staphylococcus aureus bacteraemia. Clin Microbiol Infect 20: 355-360. http://dx.doi.org/10.1111/1469-0691.12329.
75. Clerc O, Prod'hom G, Vogne C, Bizzini A, Calandra T, Greub G. 2013. Impact of matrix-assisted laser desorption ionization time-of-flight mass spectrometry on the clinical management of patients with Gram-negative bacteremia: a prospective observational study. Clin Infect Dis 56: 1101-1107. http://dx.doi.org/10.1093/cid/cis1204.
76. Huang AM, Newton D, Kunapuli A, Gandhi TN, Washer LL, Isip J, Collins CD, Nagel JL. 2013. Impact of rapid organism identification via matrix-assisted laser desorption/ionization time-of-flight combined with antimicrobial stewardship team intervention in adult patients with bacteremia and candidemia. Clin Infect Dis 57: 1237-1245. http://dx.doi.org/10.1093/cid/cit498.
77. Martiny D, Debaugnies F, Gateff D, Gerard M, Aoun M, Martin C, Konopnicki D, Loizidou A, Georgala A, Hainaut M, Chantrenne M, Dediste A, Vandenberg O, Van Praet S. 2013. Impact of rapid microbial identification directly from positive blood cultures using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry on patient management. Clin Microbiol Infect 19: E568-E581. http://dx.doi.org/10.1111/1469-0691.12282.
78. Vlek AL, Bonten MJ, Boel CH. 2012. Direct matrix-assisted laser desorption ionization time-of-flight mass spectrometry improves appropriateness of antibiotic treatment of bacteremia. PLoS One 7: e32589. http://dx.doi.org/10.1371/journal.pone.0032589.
79. Ioannidis JP. 2005. Contradicted and initially stronger effects in highly cited clinical research. JAMA 294: 218-228. http://dx.doi.org/10.1001/jama.294.2.218.
80. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, Lijmer JG, Moher D, Rennie D, de Vet HC. 2003. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for Reporting of Diagnostic Accuracy. Clin Chem 49: 1-6.
81. Whitley E, Ball J. 2002. Statistics review 4: sample size calculations. Crit Care 6: 335-341. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC137461/pdf/cc1521.pdf. (Accessed 18 April 2014.)